EQL Pharma
EQL Pharma AB successfully issues senior secured bonds
CEO Axel Schörling:
“The successful issuance of our first bond is a significant milestone for EQL Pharma. The robustness of our business model and reputation in the capital markets is highlighted by the strong interest from high-quality Nordic and international institutional investors, resulting in a significantly oversubscribed book. The bond issue allows us to finalise the previously announced acquisition of the product portfolio from Medilink. This acquisition will not only drive geographic expansion but also unlock strong synergistic potential by accessing new pan-European distribution channels, which can be deployed for our existing portfolio. Additionally, the acquisition will be highly accretive to EQL's profitability and represent an important step towards expanding our EBITDA margin, while also inherently giving rise to cost optimisation.
This milestone further strengthens my confidence and belief in EQL's strategy and future utilisation of our cost-efficient platform for driving profit growth in niche pharmaceuticals. I am very excited about the opportunities that lie ahead.”
ABG Sundal Collier AB has acted as sole bookrunner in connection with the issuance of the Bonds. Advokatfirman Vinge has acted as legal advisor.
This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-01-2025 15:45 CET.
| Datum | 2025-01-17, kl 15:45 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.